medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2009, Number 4

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2009; 7 (4)

Sneddon-Wilkinson Disease. A Case Report

Boeta ÁL, Ortiz Y, León GT, Ramírez VA

Language: Spanish
References: 25
Page: 249-252
PDF size: 255.61 Kb.


ABSTRACT

Sneddon-Wilkinson disease (subcorneal pustular dermatosis) is an uncommon disease, characterized by subcorneal neutrophil-laden pustules. We report a 63 year-old female with disseminated vesicles and pustules with rapid spreading. She had a history of diabetes and hypertension. Biopsy showed multiple subcorneal pustules with abundant polymorphonuclear leukocytes, few eosinophils and edema of the dermis. We observed remission of lesions at the third day of treatment with human recombinant immunoglobulin. We did’nt find previous reports, but based on successful in other autoimmune bullous diseases we administered at 0.3 g/kg/day for three days, which allowed remission during a follow-up of 11 months without side effects or relapses.


REFERENCES

  1. Sneddon IB, Wilkinson DS. “Subcorneal pustular dermatosis”. Br J Dermatol, 1956; 68: 385-394.

  2. Reed J, Wilkinson J. “Subcorneal pustular dermatosis”. Clin Dermatol, 2000; 18: 301-313.

  3. Tagami H, Iwatsuki K, Iwase Y et al. “Subcorneal pustular dermatosis with vesiculo-bullous eruption: Demonstration of subcorneal IgA deposits and a leukocyte chemotactic factor”. Br J Dermatol, 1983; 109: 581-587.

  4. Grob JJ, Mege JL, Capo C et al. “Role of tumor necrosis factor-alpha in Sneddon-Wilkinson subcorneal pustular dermatosis”. J Am Acad Dermatol, 1991; 25: 944-947.

  5. Voigtländer C, Lüftl M, Schuler G et al. “Infliximab (antitumor necrosis factor alpha antibody)”. Arch Dermatol, 2001; 137: 1571-1574.

  6. Berk DR, Hurt MA, Mann C et al. “Sneddon-Wilkinson disease treated with etanercept: Report of two cases”. Clin Exp Dermatol, 2009; 34(3): 347-351.

  7. Alexis AF, Strober BE. “Off-label dermatologic uses of anti-TNF-α therapies”. J Cutan Med Surg, 2005; 9(6): 296-302.

  8. Papini M, Cicoletti M, Landucci P. “Subcorneal pustular dermatosis and mycoplasma pneumoniae respiratory infection”. Acta Dermato- Venereologica, 1651-2057, vol.83, Issue 5, 2003; 387 – 388.

  9. Roger H, Thevenet JP, Souteyrand P et al. “Subcorneal pustular dermatosis associated with rheumatoid arthritis and raised IgA: Simultaneous remission of skin and joint involvements with dapsone treatment”. Ann Rheum Dis, 1990; 49: 190-191.

  10. Kasha EE, Epinette WW. “Subcorneal pustular dermatosis (Sned - don-Wilkinson disease) in association with a monoclonal gammopathy: A report and review of the literature”. J Am Acad Dermatol, 1998; 19: 854-858.

  11. Takata M, Inaoki M, Shodo M et al. “Subcorneal pustular dermatosis associated with IgA myeloma and intraepidermal IgA deposits”. Dermatology 1994; 189(supl. 1): 111-114.

  12. Butt A, Burge SM. “Sneddon-Wilkinson disease in association with rheumatoid arthritis”. Br J Dermatol 1995; 132: 313-315.

  13. Ratnarathorn M, Newman J. “Subcorneal pustular dermatosis (Sned - don-Wilkinson disease) occurring in association with nodal marginal zone lymphoma: A case report”. Dermatol Online J 2008; 14(8): 6.

  14. Agarwal A, Shivaswamy KN. “Subcorneal pustular dermatosis and thy moma: An associaton or coincidence?” Indian J Dermatol 2006; 51(4): 272-274.

  15. Cheng S, Edmonds E, Ben-Gashir M et al. “Subcorneal pustular dermatosis: 50 years on”. Clin Exp Dermatol 2008; 33(3): 229-233.

  16. Koasak M. “Juvenile subcorneal pustular dermatosis: a case report. Pediatr Dermatol 2003; 20(1): 57-59.

  17. Saúl A, Salazar E. “Pustulosis subcórnea de Sneddon y Wilkinson”. Dermatología Rev Méx 1962; 6(3): 261-275.

  18. Kandolf-Sekulovic L, Mijuskovic ZP, Zecevic RD. “Subcorneal pustular dermatosis: Review of 11 patients”. JEADV 2003; 17(supl. 3): 198.

  19. Bonifati C, Trento E, Cordiali FP et al. “Early but not lasting improvement of recalcitrant subcorneal pustular dermatosis (Sneddon- Wilkinson disease) after infliximab therapy: Relationships with variations cytokine levels in suction blister fluids”. J Clin Exp Dermatol 2005; 30: 662-665.

  20. Bedi MK. “Successful treatment of long-standing, recalcitrant subcorneal pustular dermatosis with etanercept”. SKINmed 2007; 6(5): 245-247.

  21. Khachemoune A, Blyumin ML. “Sneddon-Wilkinson disease resistant to dapsone and colchicine successfully controlled with PUVA”. Dermatol Online J 2003; 9(5): 24.

  22. Jolles S. “High-dose intravenous immunoglobulin (hdIVIg) in the treat ment of autoimmune blistering disorders”. Clin Exp Immunol 2002; 129: 385-389.

  23. Mogica MM. “Uso terapéutico actual de la inmunoglobulina intravenosa”. Rev Med Inst Mex Seguro Soc 2006; 44(supl. 2): 81-86.

  24. Jaime R, Peralta C, Dahbar M y cols. “Pustulosis exantemática aguda generalizada”. Act Terap Dermatol 2007; 30: 23.

  25. Schmid S, Kuechler PC, Britschgi M et al. “Acute generalized exanthematous pustulosis. Role of cytotoxic T cells in pustule formation”. AJP 2002; 161(6): 2079-2086.




2020     |     www.medigraphic.com